Avalo Therapeutics (AVTX) Revenue (2016 - 2025)

Avalo Therapeutics posted quarterly Revenue of $59000.0 for Q4 2025, down 69.27% year-on-year from $192000.0 in Q4 2024, and down 69.27% on a QoQ basis from $192000.0 in Q4 2024.

Avalo Therapeutics (AVTX) has 10 years of Revenue data on file, last reported at $59000.0 in Q4 2025.

  • For the quarter ending Q4 2025, Revenue fell 69.27% year-over-year to $59000.0; the trailing twelve-month figure through Dec 2025 stood at $500000.0 (up 13.38% YoY), and the FY2025 full-year result was $59000.0, down 86.62% from the prior year.
  • Revenue for Q4 2025 stood at $59000.0, down from $192000.0 in the prior quarter.
  • Across five years, Revenue topped out at $14.9 million in Q3 2022 and bottomed at $59000.0 in Q4 2025.
  • The 5-year median for Revenue is $571000.0 (2023), against an average of $1.7 million.
  • The widest annual swing landed in 2022, when Revenue surged 1007.33%; it then tumbled 98.42% in 2023.
  • A 5-year view of Revenue shows it stood at $219000.0 in 2021, then soared by 309.13% to $896000.0 in 2022, then tumbled by 36.27% to $571000.0 in 2023, then sank by 66.37% to $192000.0 in 2024, then slumped by 69.27% to $59000.0 in 2025.
  • The last three Revenue figures came in at $59000.0 (Q4 2025), $192000.0 (Q4 2024), and $249000.0 (Q3 2024), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Revenue (Qtr)
1 Quantum Biopharma 961,148.99 Bn 961,148.98 Bn - -
2 Alterity Therapeutics 744,933.29 Bn 744,933.26 Bn - -
3 Legend Biotech 2,540.00 Bn 2,539.71 Bn 242.10 Mn 306.30 Mn
4 Nanobiotix 2,199.85 Bn 2,199.78 Bn - -
5 Akari Therapeutics 1,635.88 Bn 1,635.88 Bn - -
6 Vertex Pharmaceuticals 111.32 Bn 104.07 Bn 2.59 Bn 2.99 Bn
7 Evaxion A 62.56 Bn 62.54 Bn - -
8 Regeneron Pharmaceuticals 62.55 Bn 53.79 Bn 3.31 Bn 3.61 Bn
9 Alnylam Pharmaceuticals 39.57 Bn 36.56 Bn 959.66 Mn 1.17 Bn
10 Avalo Therapeutics 317.29 Mn 317.29 Mn - -

Historic Data

Download Data 🔒
DateValue
Dec 31, 2025 59,000.00
Dec 31, 2024 192,000.00
Sep 30, 2024 249,000.00
Dec 31, 2023 571,000.00
Sep 30, 2023 236,000.00
Jun 30, 2023 643,000.00
Mar 31, 2023 475,000.00
Dec 31, 2022 896,000.00
Sep 30, 2022 14.95 Mn
Jun 30, 2022 1.03 Mn
Mar 31, 2022 1.17 Mn
Dec 31, 2021 219,000.00
Sep 30, 2021 1.35 Mn
Jun 30, 2021 3.36 Mn
Mar 31, 2021 473,000.00
Dec 31, 2020 1.50 Mn
Sep 30, 2020 1.11 Mn
Jun 30, 2020 1.34 Mn
Mar 31, 2020 2.75 Mn
Dec 31, 2019 580,808.00
Sep 30, 2019 2.20 Mn
Jun 30, 2019 1.39 Mn
Mar 31, 2019 2.58 Mn
Dec 31, 2018 -6.31 Mn
Sep 30, 2018 4.07 Mn
Jun 30, 2018 4.79 Mn
Mar 31, 2018 4.48 Mn
Dec 31, 2017 1.91 Mn
Sep 30, 2017 25.04 Mn
Jun 30, 2017 157,800.00
Mar 31, 2017 384,206.00
Dec 31, 2016 182,000.00
Sep 30, 2016 321,497.00
Jun 30, 2016 650,488.00